Mode
Text Size
Log in / Sign up

Natural products offer multi-target renoprotective effects for metabolic, inflammatory, and oxidative stress pathwaysNatural compounds show promise for kidney disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that natural products may offer multi-target renoprotection despite limited bioavailability and insufficient safety data.

This systematic review evaluates the potential of various natural products, including polysaccharides, flavonoids, phenolic acids, triterpenes, alkaloids, and saponins, for managing conditions such as diabetic kidney disease, obesity-related glomerulopathy, and hyperuricemic nephropathy. The authors synthesize evidence suggesting these compounds may offer renoprotective effects by coordinating the modulation of several interconnected pathways, specifically metabolic dysregulation, gut microbiota imbalance, oxidative stress, mitochondrial dysfunction, chronic inflammation, and renal fibrosis.

The review notes that while these multi-target regulatory characteristics make natural products promising candidates for integrated management, significant limitations exist. These include limited bioavailability, incompletely characterized pharmacokinetic properties, and a lack of high-quality clinical evidence. Additionally, the authors highlight that safety evaluations are currently insufficient.

Clinical application is currently limited by the need for more robust data. While these compounds show promise as multi-target agents compared to conventional single-pathway interventions, their role in clinical practice requires further investigation into pharmacokinetic profiles and large-scale safety assessments.

How this fits prior evidence

This systematic review addresses a gap in the management of metabolic kidney diseases by exploring natural products with multi-target characteristics. While previous coverage noted that Citrus grandis Tomentosa flavonoids show preclinical promise for MASLD but lack sufficient data for clinical translation, this review explores similar multi-target mechanisms for renal conditions like diabetic kidney disease and obesity-related glomerulopathy.

A new review of existing research suggests that natural compounds found in plants could offer a new way to protect the kidneys in people with diabetic kidney disease and related conditions. The review looked at studies on compounds like polysaccharides, flavonoids, and saponins. These natural products appear to work by targeting several disease processes at the same time, including metabolic problems, gut bacteria imbalance, oxidative stress, and inflammation.

The review did not include new patient data. Instead, it summarized findings from earlier studies. The researchers compared natural products to conventional treatments that usually target only one pathway. They found that natural products may have broader effects, potentially leading to better kidney protection.

However, the review also points out important limitations. Many natural compounds are not well absorbed by the body, and their safety has not been fully studied. There is a lack of high-quality clinical trials in humans. The authors caution that more research is needed before these compounds can be recommended for treatment.

For now, the findings are promising but early. People with kidney disease should not replace their current treatments with natural products without talking to their doctor. The review highlights a potential new direction for future therapies, but it is not a reason to change current care.

What this means for you:
Natural compounds may help kidneys, but more human studies are needed.

Common questions

What natural compounds were studied?

The review looked at polysaccharides, flavonoids, phenolic acids, triterpenes, alkaloids, and saponins. These are compounds found in various plants and herbs.

Are natural products safe for kidney disease?

The review says natural products generally have favorable safety and tolerability profiles, but it also notes limited bioavailability and insufficient safety evaluation. More research is needed.

How do natural products compare to standard treatments?

Standard treatments often target one pathway, while natural products may work on multiple processes like inflammation and oxidative stress. However, there is a lack of high-quality clinical evidence comparing them directly.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
Metabolic dysfunction–associated kidney disease (MDAKD), encompassing diabetic kidney disease (DKD), obesity-related glomerulopathy (ORG), and hyperuricemic nephropathy (HN), has emerged as a major global health challenge alongside the increasing prevalence of metabolic syndrome. The development and progression of MDAKD are driven by a complex pathogenic network involving metabolic dysregulation, gut microbiota imbalance, oxidative stress, mitochondrial dysfunction, chronic inflammation, and renal fibrosis. Although previous reviews have focused on individual pathogenic mechanisms or specific disease subtypes, comprehensive syntheses integrating distinct MDAKD subtypes within a unified framework while systematically elucidating the multidimensional regulatory mechanisms of natural products remain limited. Natural products have attracted growing attention owing to their multi-component and multi-target pharmacological properties. Increasing evidence suggests that their therapeutic potential extends beyond the modulation of individual pathogenic pathways, encompassing the coordinated regulation of multiple interconnected pathological networks. Diverse bioactive constituents, including polysaccharides, flavonoids, phenolic acids, triterpenes, alkaloids, and saponins, have demonstrated considerable renoprotective effects. Compared with conventional single-pathway interventions, the multi-target regulatory characteristics of natural products, together with their generally favorable safety and tolerability profiles, make them particularly suited to the multifactorial nature of MDAKD. This review systematically summarizes the key pathogenic mechanisms underlying MDAKD and comprehensively discusses recent advances in natural product–based interventions from both mechanistic and pharmacological perspectives. Current evidence indicates that natural products exert renoprotective effects through the coordinated modulation of multiple interconnected pathological processes, thereby establishing a multidimensional regulatory pattern that closely aligns with the complex pathophysiology of MDAKD. Despite challenges related to limited bioavailability, incompletely characterized pharmacokinetic properties, insufficient safety evaluation, and the lack of high-quality clinical evidence, natural products remain promising candidates for the integrated management of MDAKD. Accordingly, this review proposes a multidimensional regulatory framework for natural product–mediated interventions in MDAKD, providing a theoretical basis for future mechanistic studies, drug development, and clinical research.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.